BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 37305016)

  • 21. The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
    Deng R; Zuo C; Li Y; Xue B; Xun Z; Guo Y; Wang X; Xu Y; Tian R; Chen S; Liu Q; Chen J; Wang J; Huang X; Li H; Guo M; Wang X; Yang M; Wu Z; Wang J; Ma J; Hu J; Li G; Tang S; Tu Z; Ji H; Zhu H
    Cell Mol Immunol; 2020 Nov; 17(11):1163-1179. PubMed ID: 32963356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
    Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
    Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of inactivated glycogen synthase kinase 3β in HPV-associated cervical cancer: Relationship with Wnt/β-catenin pathway activation.
    Rath G; Jawanjal P; Salhan S; Nalliah M; Dhawan I
    Am J Reprod Immunol; 2015 May; 73(5):460-78. PubMed ID: 25532422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
    Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
    Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
    Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
    Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.
    Chen Z; Pang N; Du R; Zhu Y; Fan L; Cai D; Ding Y; Ding J
    Mediators Inflamm; 2016; 2016():6891482. PubMed ID: 27721577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
    Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
    J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV: Molecular pathways and targets.
    Gupta S; Kumar P; Das BC
    Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.
    Mezache L; Paniccia B; Nyinawabera A; Nuovo GJ
    Mod Pathol; 2015 Dec; 28(12):1594-602. PubMed ID: 26403783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. β-Catenin: oncogenic role and therapeutic target in cervical cancer.
    Wang B; Li X; Liu L; Wang M
    Biol Res; 2020 Aug; 53(1):33. PubMed ID: 32758292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of Wnt/β-catenin Pathway Elevates the Sensitivity of Gastric Cancer Cells to PD-1 Antibody.
    Li J; Zhang H; Bei S; Zhang X; Li H; Ye L; Feng L
    Curr Mol Pharmacol; 2022; 15(3):557-569. PubMed ID: 34139974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
    Ottenhof SR; Djajadiningrat RS; de Jong J; Thygesen HH; Horenblas S; Jordanova ES
    J Urol; 2017 Mar; 197(3 Pt 1):690-697. PubMed ID: 27697578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.